Clinical Report: FDA approves FET-PET agent for glioma
Overview
The FDA has approved floretyrosine F 18 (Pixclara) for PET imaging to differentiate recurrent glioma from treatment-related changes in patients aged 1 month or older. This marks the first FDA approval of an FET-PET imaging drug for glioma.
Background
Gliomas are the most common primary tumors of the central nervous system, with approximately 24,000 new cases diagnosed annually in the US. Accurate differentiation between recurrent glioma and treatment-related changes is critical. The approval of floretyrosine F 18 aligns with international guidelines recommending its use in glioma imaging.
Data Highlights
Floretyrosine F 18 was evaluated in 382 patients with gliomas, including 371 adults and 11 pediatric patients. The safety profile showed headache in 0.5% of patients, with nausea, injection-site reaction, fatigue, and malaise occurring in fewer than 0.5%.
Key Findings
Floretyrosine F 18 is the first FDA-approved FET-PET imaging agent for glioma.
Approximately 24,000 new glioma cases are diagnosed annually in the US.
Image misinterpretation may occur, necessitating the incorporation of other diagnostic information.
Floretyrosine F 18 adds to cumulative radiation exposure, which is associated with an increased risk of cancer.
Clinical Implications
The approval of floretyrosine F 18 provides clinicians with a new tool for distinguishing between recurrent glioma and treatment-related changes.
Conclusion
The FDA's approval of floretyrosine F 18 supports the use of FET-PET imaging in glioma.
